Equities

LivaNova PLC

LivaNova PLC

Actions
Health CareMedical Equipment and Services
  • Price (USD)53.00
  • Today's Change1.19 / 2.30%
  • Shares traded631.11k
  • 1 Year change+15.72%
  • Beta0.9771
Data delayed at least 15 minutes, as of Nov 12 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year LivaNova PLC grew revenues 12.89% from 1.02bn to 1.15bn while net income improved from a loss of 86.25m to a gain of 17.55m.
Gross margin67.78%
Net profit margin1.91%
Operating margin-2.19%
Return on assets0.98%
Return on equity1.87%
Return on investment1.12%
More ▼

Cash flow in USDView more

In 2023, LivaNova PLC increased its cash reserves by 12.07%, or 62.25m. The company earned 74.91m from its operations for a Cash Flow Margin of 6.49%. In addition the company generated 21.48m cash from financing while 40.33m was spent on investing.
Cash flow per share1.25
Price/Cash flow per share41.46
Book value per share24.13
Tangible book value per share5.16
More ▼

Balance sheet in USDView more

LivaNova PLC has a Debt to Total Capital ratio of 32.34%, a lower figure than the previous year's 46.36%.
Current ratio3.37
Quick ratio2.87
Total debt/total equity0.478
Total debt/total capital0.3234
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.